Dicerna's DCR-PHXC reduces urinary oxalate levels in Phase I

Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) reported interim six-week data from the Phase I PHYOX trial showing that single subcutaneous doses of DCR-PHXC brought urinary oxalate levels into the normal or near-normal range in five of eight evaluable patients with primary hyperoxaluria. All eight patients achieved a >30% reduction in urinary oxalate levels from baseline. DCR-PHXC was well tolerated. The company plans to present detailed data from PHYOX in 4Q18.

Dicerna’s lead programs are designed to silence disease-driving genes in the liver and are based on the company's GalXC technology, which allows attachment of N-acetylgalactosamine sugars to the extended region of RNAi molecules. DCR-PHXC is a subcutaneously delivered RNAi-based therapeutic using GalXC that selectively silences lactate dehydrogenase A (LDHA) in the liver...